한글목차

펩타이드 API 시장 - 조사 범위

TMR의 조사 보고서 "세계 펩타이드 API 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사합니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지의 세계 펩타이드 API 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 펩타이드 API 시장의 복합 연간 성장률(CAGR %)도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 펩타이드 API 시장을 이해하고자 했습니다.

이 보고서는 세계 펩타이드 API 시장의 경쟁 환경을 조사하고 있습니다. 세계 펩타이드 API 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등이 이 보고서에서 소개하는 세계 펩타이드 API 시장의 기업 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 소개
• 개요
• 시장 역학
• 세계의 시장 분석과 예측, 2020-2034

제5장 주요 인사이트

• 주요 국가·지역의 당뇨병과 비만 역학
• GLP-1 수용체 작용제 치료 업계의 최근 기술 진보
• 인슐린 치료 산업의 최근 기술 진보
• GLP-1 수용체 작용제 치료제 가격 동향
• 인슐린 치료제 가격 동향
• 임상시험 분석

제6장 세계의 시장 분석과 예측 : 약물 종류별

• 소개와 정의
• 주요 조사 결과/ 진전
• 약물 종류별 시장 가치, 수량, 환자 수 예측, 2020-2034년
  • GLP-1 수용체 작용제
  • 인슐린
  • 기타 펩타이드 클래스
• 약물 종류별 시장 매력

제7장 세계의 시장 분석과 예측 : 제품 유형별

• 소개와 정의
• 주요 조사 결과/ 진전
• 제품 유형별 시장 가치, 수량, 환자 수 예측, 2020-2034년
  • GLP-1 수용체 작용제 경구 제제
  • GLP-1 수용체 작용제 주사제
  • 인슐린 주사제
  • 기타 펩타이드
• 제품 유형별 시장 매력

제8장 세계의 시장 분석과 예측 : 투여 경로별

• 소개와 정의
• 주요 조사 결과/ 진전
• 투여 경로별 시장 가치, 수량, 환자 수 예측, 2020-2034년
  • 경구
  • 비경구
• 투여 경로별 시장 매력

제9장 세계의 시장 분석과 예측 : 용도별

• 소개와 정의
• 주요 조사 결과/ 진전
• 용도별 시장 가치, 수량, 환자 수 예측, 2020-2034년
  • 2형 당뇨병
  • 1형 당뇨병
  • 비만
  • 비알코올성 지방간 질환
  • 기타
• 용도별 시장 매력

제10장 세계의 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 지역별 시장 가치, 수량, 환자 수 예측
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 지역별 시장 매력

제11장 북미의 시장 분석과 예측

제12장 경쟁 상황

• 시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
• 시장 점유율 분석 기업별(2023)
• Competitive Dashboard
  • By Drug Class
• Competitive Snapshot
• 기업 개요
  • Eli Lilly and Company
  • Sanofi S.A.
  • Novo Nordisk
  • AstraZeneca
  • GlaxoSmithKline
  • PegBio Co. Ltd.
  • Amgen Inc.
  • Pfizer Inc.
  • Innovent Biologics, Inc.
  • Sun Pharmaceutical Industries Limited
  • Boehringer Ingelheim
  • Biocon Limited
  • Wockhardt

영문목차

Peptide API Market - Scope of Report

TMR's report on the global peptide API market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global peptide API market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide API market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide API market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide API market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide API market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide API market.

The report delves into the competitive landscape of the global peptide API market. Key players operating in the global peptide API market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide API market profiled in this report.

Key Questions Answered in Global peptide API Market Report:

• What is the sales/revenue generated by peptide API across all regions during the forecast period?
• What are the opportunities in the global peptide API market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Peptide API Market - Research Objectives and Research Approach

The comprehensive report on the global peptide API market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide API market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide API market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Peptide API Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Peptide API Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Value (US$ Bn) and Volume Projections (Kg)

5. Key Insights

• 5.1. Epidemiology of Diabetes and Obesity across Key Countries / Regions
• 5.2. Recent Technological Advancements in GLP-1 Receptor Agonist Therapeutics Industry
• 5.3. Recent Technological Advancements in Insulin Therapeutics Industry
• 5.4. GLP-1 Receptor Agonist Therapeutics Pricing Trends
• 5.5. Insulin Therapeutics Pricing Trends
• 5.6. Clinical Trials Analysis

6. Global Peptide API Market Analysis and Forecasts, By Drug Class

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value, Volume and Patient Population Forecast By Drug Class, 2020-2034
  • 6.3.1. GLP-1 Receptor Agonist
  • 6.3.2. Insulin
  • 6.3.3. Other Peptide Classes
• 6.4. Market Attractiveness By Drug Class

7. Global Peptide API Market Analysis and Forecasts, By Product Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value, Volume and Patient Population Forecast By Product Type, 2020-2034
  • 7.3.1. GLP-1 Receptor Agonist Oral Formulations
  • 7.3.2. GLP-1 Receptor Agonist Injectables
  • 7.3.3. Insulin Injectables
  • 7.3.4. Other Peptides
• 7.4. Market Attractiveness By Product Type

8. Global Peptide API Market Analysis and Forecasts, By Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value, Volume and Patient Population Forecast By Route of Administration, 2020-2034
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Attractiveness By Route of Administration

9. Global Peptide API Market Analysis and Forecasts, By Application

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value, Volume and Patient Population Forecast By Application, 2020-2034
  • 9.3.1. Type 2 Diabetes Mellitus
  • 9.3.2. Type 1 Diabetes
  • 9.3.3. Obesity
  • 9.3.4. Non-alcoholic Fatty Liver Disease
  • 9.3.5. Others
• 9.4. Market Attractiveness By Application

10. Global Peptide API Market Analysis and Forecasts, By Region

• 10.1. Key Findings
• 10.2. Market Value, Volume and Patient Population Forecast By Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Region

11. North America Peptide API Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value, Volume and Patient Population Forecast By Drug Class, 2020-2034
  • 11.2.1. GLP-1 Receptor Agonist
  • 11.2.2. Insulin
  • 11.2.3. Other Peptide Classes
• 11.3. Market Value, Volume and Patient Population Forecast By Product Type, 2020-2034
  • 11.3.1. GLP-1 Receptor Agonist Oral Formulations
  • 11.3.2. GLP-1 Receptor Agonist Injectables
  • 11.3.3. Insulin Injectables
  • 11.3.4. Other Peptides
• 11.4. Market Value, Volume and Patient Population Forecast By Route of Administration, 2020-2034
  • 11.4.1. Oral
  • 11.4.2. Parenteral
• 11.5. Market Value, Volume and Patient Population Forecast By Application, 2020-2034
  • 11.5.1. Type 2 Diabetes Mellitus
  • 11.5.2. Type 1 Diabetes
  • 11.5.3. Obesity
  • 11.5.4. Non-alcoholic Fatty Liver Disease
  • 11.5.5. Others
• 11.6. Market Value, Volume and Patient Population Forecast By Country, 2020-2034
  • 11.6.1. U.S.
  • 11.6.2. Canada

12. Competition Landscape

• 12.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 12.2. Market Share Analysis By Company (2023)
• 12.3. Competitive Dashboard
  • 12.3.1. By Region
  • 12.3.2. By Drug Class
• 12.4. Competitive Snapshot
• 12.5. Company Profiles
  • 12.5.1. Eli Lilly and Company
    • 12.5.1.1. Company Overview
    • 12.5.1.2. Financial Overview
    • 12.5.1.3. Product Portfolio
    • 12.5.1.4. Business Strategies
    • 12.5.1.5. Recent Developments
  • 12.5.2. Sanofi S.A.
    • 12.5.2.1. Company Overview
    • 12.5.2.2. Financial Overview
    • 12.5.2.3. Product Portfolio
    • 12.5.2.4. Business Strategies
    • 12.5.2.5. Recent Developments
  • 12.5.3. Novo Nordisk
    • 12.5.3.1. Company Overview
    • 12.5.3.2. Financial Overview
    • 12.5.3.3. Product Portfolio
    • 12.5.3.4. Business Strategies
    • 12.5.3.5. Recent Developments
  • 12.5.4. AstraZeneca
    • 12.5.4.1. Company Overview
    • 12.5.4.2. Financial Overview
    • 12.5.4.3. Product Portfolio
    • 12.5.4.4. Business Strategies
    • 12.5.4.5. Recent Developments
  • 12.5.5. GlaxoSmithKline
    • 12.5.5.1. Company Overview
    • 12.5.5.2. Financial Overview
    • 12.5.5.3. Product Portfolio
    • 12.5.5.4. Business Strategies
    • 12.5.5.5. Recent Developments
  • 12.5.6. PegBio Co. Ltd.
    • 12.5.6.1. Company Overview
    • 12.5.6.2. Financial Overview
    • 12.5.6.3. Product Portfolio
    • 12.5.6.4. Business Strategies
    • 12.5.6.5. Recent Developments
  • 12.5.7. Amgen Inc.
    • 12.5.7.1. Company Overview
    • 12.5.7.2. Financial Overview
    • 12.5.7.3. Product Portfolio
    • 12.5.7.4. Business Strategies
    • 12.5.7.5. Recent Developments
  • 12.5.8. Pfizer Inc.
    • 12.5.8.1. Company Overview
    • 12.5.8.2. Financial Overview
    • 12.5.8.3. Product Portfolio
    • 12.5.8.4. Business Strategies
    • 12.5.8.5. Recent Developments
  • 12.5.9. Innovent Biologics, Inc.
    • 12.5.9.1. Company Overview
    • 12.5.9.2. Financial Overview
    • 12.5.9.3. Product Portfolio
    • 12.5.9.4. Business Strategies
    • 12.5.9.5. Recent Developments
  • 12.5.10. Sun Pharmaceutical Industries Limited
    • 12.5.10.1. Company Overview
    • 12.5.10.2. Financial Overview
    • 12.5.10.3. Product Portfolio
    • 12.5.10.4. Business Strategies
    • 12.5.10.5. Recent Developments
  • 12.5.11. Boehringer Ingelheim
    • 12.5.11.1. Company Overview
    • 12.5.11.2. Financial Overview
    • 12.5.11.3. Product Portfolio
    • 12.5.11.4. Business Strategies
    • 12.5.11.5. Recent Developments
  • 12.5.12. Biocon Limited
    • 12.5.12.1. Company Overview
    • 12.5.12.2. Financial Overview
    • 12.5.12.3. Product Portfolio
    • 12.5.12.4. Business Strategies
    • 12.5.12.5. Recent Developments
  • 12.5.13. Wockhardt
    • 12.5.13.1. Company Overview
    • 12.5.13.2. Financial Overview
    • 12.5.13.3. Product Portfolio
    • 12.5.13.4. Business Strategies
    • 12.5.13.5. Recent Developments